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Due to changes in glycosyltransferase expression during oncogenesis, the glycoproteins
of cancer cells often carry highly truncated carbohydrate chains compared to those
on healthy cells. These glycans are known as tumor-associated carbohydrate antigens
(TACAs), and are prime targets for use in vaccines for the prevention and treatment
of cancer. Herein, we review the state-of-the-art in targeting the immune system
toward tumor-associated glycopeptide antigens via synthetic self-adjuvanting vaccines,
in which the antigenic and adjuvanting moieties of the vaccines are present in the same
molecule. The majority of the self-adjuvanting glycopeptide cancer vaccines reported
to date employ antigens from mucin 1, a protein which is highly over-expressed and
aberrantly glycosylated in many forms of cancer. The adjuvants used in these vaccines
predominantly include lipopeptide- or lipoamino acid-based TLR2 agonists, although
studies investigating stimulation of TLR9 and TLR4 are also discussed. Many of these
adjuvants are highly lipophilic, and, upon conjugation to antigenic peptides, provide
amphiphilic vaccine molecules. The amphiphilic nature of these vaccine constructs can
lead to the formation of higher-order structures by vaccines in solution, which are likely
to be important for their efficacy in vivo.
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INTRODUCTION
It is well-established that immunological surveillance is an important method by which cancer is
controlled in healthy people. As such, tumor immunology and immunotherapy have emerged as
exciting new opportunities for the prevention and treatment of malignancy (Lizée et al., 2013). To
date, researchers have sought to use tumor-associated antigens (TAAs) to induce or boost tumor
immunity with a view to preventing or treating malignancy. However, as most of the antigens
expressed by cancer cells are mutated or over-expressed self-antigens, any attempt to utilize the
immune system to clear cancer must first overcome the major hurdle of immunological self-
tolerance. Vaccination strategies seek to break tolerance to particular TAAs and induce long-lived
adaptive immune responses. As a result, the antigens chosen for the development of a cancer
vaccine must be unique to, or highly over-expressed in, cancer cells compared to healthy tissue
(Cheever et al., 2009).
The glycocalyx of healthy epithelial tissues is comprised of densely glycosylated glycoproteins.
The glycosylation of these proteins is controlled by the relative concentrations and activities
of glycosyltransferases, and mucinous proteins are typically decorated with elongated, branched
carbohydrate chains (Shimizu and Yamauchi, 1982). During cancer, changes in the expression
of key glycosyltransferases can lead to expression of heavily truncated O-linked glycans known
McDonald et al. Self-adjuvanting glycopeptide cancer vaccines
as tumor-associated carbohydrate antigens (TACAs) appended
to the peptide backbones of these mucin-type glycoproteins
(Meezan et al., 1969; Dennis et al., 1999). Such TACAs include
the mono-saccharidyl TN and di-saccharidyl T antigens and their
sialylated derivatives (Sialyl-TN, 2,3-Sialyl-T, and 2,6-Sialyl-T),
which arise from over-expression of sialyltransferases (Figure 1).
Several mucin (MUC) glycoproteins have been shown to be
overexpressed during cancer (Torres et al., 2012) and have
therefore been targeted in cancer vaccines, including MUC1
(Kimura and Finn, 2013), MUC4 (Cai et al., 2015), MUC5AC
(Zhu et al., 2009), and MUC16 (Reinartz et al., 2003). MUC1,
however, is by far the most commonly studied of these antigens
for vaccine development.
MUC1
MUC1 is a single-pass transmembrane glycoprotein expressed
on the apical surface of normal epithelial cells. The extracellular
domain of MUC1 contains between 25 and 125 repeats of a
20-amino acid-residue variable number tandem repeat (VNTR)
sequence GVTSAPDTRPAPGSTAPPAH. Serine and threonine
residues within this repeat are O-glycosylated with elongated
carbohydrate chains, and each potential glycosylation site can
contain glycans in vivo (Muller et al., 1997). In many cancers,
MUC1 is aberrantly glycosylated and highly overexpressed
(Kufe, 2009). Tumor expression of MUC1 is correlated with
reduced survival of renal cell carcinoma patients (Fujita et al.,
1999) and increased metastatic ability of many cancers (Horm
and Schroeder, 2013). For these reasons, MUC1 is considered
FIGURE 1 | Structures of common tumor-associated carbohydrate antigens (TACAs).
a promising antigen in the development of effective cancer
vaccines. However, the inherent heterogeneity of glycosylation
means that chemically uniform MUC1 glycopeptides cannot
be isolated, and must instead be chemically synthesized. One
approach to generate vaccines incorporating synthetic MUC1
glycopeptides involves the conjugation of MUC1 glycopeptides
to carrier proteins such as bovine serum albumin (Cai et al.,
2011), keyhole limpet hemocyanin (Adluri et al., 1999), and
tetanus toxoid (Kaiser et al., 2009). Such vaccines have been
reviewed previously (Gaidzik et al., 2013), and will not be
discussed in detail here. Instead, this mini-review will highlight
recent research aimed at the development of synthetic self-
adjuvanting vaccines.
Self-adjuvanting Vaccines
In order to properly activate antigen-presenting cells (APCs)
such as dendritic cells and macrophages toward the priming of
cytotoxic and helper T cells (CTLs and Th cells, respectively),
vaccines usually incorporate an adjuvant which can stimulate
APCs via pattern-recognition receptors. Adjuvants are thought
to be a necessary feature to make cancer vaccines immunogenic
enough to break through immunological self-tolerance to tumor
antigens (Mesa and Fernández, 2004). While traditional vaccines
are formulated into mixtures of an antigen plus an adjuvant,
vaccines in which the two moieties are contained within a single
molecule are dubbed self-adjuvanting vaccines. Such vaccines
have an advantage over traditional vaccines in that they are taken
up by APCs faster (Zhu et al., 2004), while ensuring that the APCs
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activated by the adjuvant are the same APCs exposed to antigen.
Another major advantage is that self-adjuvanting vaccines avoid
the use of highly toxic adjuvants such as complete Freund’s
adjuvant (CFA) while still eliciting potent immune responses
(Chua et al., 2014). In experimental models, these approaches
have proved beneficial in vaccines against cancer (Le Gal et al.,
2002; Liu et al., 2013), infectious diseases (Batzloff et al., 2006;
Bettahi et al., 2006), and allergy (Anderson et al., 2014), and
have been reviewed previously (BenMohamed et al., 2002; Brown
and Jackson, 2005; Moyle and Toth, 2008; Chentoufi et al.,
2009).
SELF-ADJUVANTING GLYCOPEPTIDE
CANCER VACCINES
Antigens
The studies reviewed here focus on the induction of
immunological responses to TACAs and glycopeptides bearing
these glycan structures by self-adjuvanting vaccines (Figure 2).
Early self-adjuvanting glycopeptide cancer vaccines consisted of
clustered TACAs linked via spacers to tri-palmitoylated cysteine
(Pam3Cys) (Toyokuni et al., 1994; Kuduk et al., 1998). These
vaccines induced TACA-specific antibodies, predominantly of
the IgM isotype. Inclusion of a Th epitope led to the induction of
high titers of class-switched IgG antibodies, but did not induce
any cellular anti-cancer immunity because no CD8+ T cell
epitopes were included (Buskas et al., 2005; Abdel-Aal et al.,
2012).
Boons and coworkers have reported the use of the
immunodominant epitope SAPDT∗RPAP (Where T∗ indicates
a threonine residue glycosylated with TACAs) conjugated to
a polio Th epitope and Pam3Cys (Ingale et al., 2007). This
9-mer binds H-2Kb in mice (Apostolopoulos et al., 1997a)
and contains the human leukocyte antigen (HLA)-A2-binding
epitope APDTRPA (Apostolopoulos et al., 1997b). Additionally,
the peptide contains the immunodominant MUC1 B cell epitope
PDT∗RP. When formulated into liposomes and injected into
mice, these vaccines gave rise to high titers of MUC1-specific
antibodies, as well as up-regulation of tumor necrosis factor
(TNF), CD83, and the co-stimulatory molecules CD80 and
CD86. Importantly, the authors have recently demonstrated
induction of CTL responses and inhibition of mouse mammary
tumor growth in response to these vaccines (Lakshminarayanan
et al., 2012).
We and others have used full 20-amino acid residue
MUC1VNTR peptides in self-adjuvanting vaccines. Kunz
and coworkers reported the induction of MUC1-specific
antibodies in response to vaccination with CFA and a Pam3Cys-
MUC1VNTR conjugate containing a full copy of the VNTR
(PAHGVT∗SAPDTRPAPGSTAP) glycosylated with TN, T, or
2,6-ST at a single Thr residue within the VNTR (indicated by
asterisk) (Kaiser et al., 2010). We incorporated a per-glycosylated
MUC1 epitope (GVT∗S∗APDT∗RPAPGS∗T∗APPAH), whereby
FIGURE 2 | Examples of self-adjuvanting TACA and glycopeptide cancer vaccines discussed in this mini-review article.
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all possible glycosylation sites were occupied with TACAs
(indicated by asterisks), in order to maximize the potential
recognition of glycopeptide tumor-associated epitopes
(Wilkinson et al., 2011). Vaccines containing per-glycosylated
MUC1 antigens, when injected in PBS without external adjuvant
or formulation into liposomes, induced high titers of MUC1
antibodies capable of recognizing MCF-7 breast cancer cells.
CD8+ T cell responses were not observed, possibly due to
over-glycosylation of the VNTR backbone leading to reduced
presentation of CD8+ T cell epitopes. Li and coworkers
used vaccines containing full-length MUC1VNTR epitopes
glycosylated variably at a Ser and/or Thr residue within the
VNTR (HGVTSAPDT∗RPAPGS∗TAPPA) to induce IgG
antibodies capable of recognizing tumor cells (Cai et al., 2014).
However, while these were capable of inducing antibody-
dependent cell-mediated cytotoxicity (ADCC), no CD8+ T cell
responses were reported for these vaccines. It is worth noting
that different MUC1VNTR sequences were used in each of
these studies, and each vaccine consequently contained different
possible T and B cell antigens. In the future, we envisage that use
of longer VNTR peptides containing overlapping repeats will
be important to cover the full range of epitopes in the VNTR
sequence.
Multi-antigenic Vaccines
A necessary feature of self-adjuvanting vaccines is that they target
the immune system to particular, well-definedmolecular epitopes
such as tumor-associated glycoforms of the MUC1VNTR. This
can be problematic, since mutation or down-regulation of
tumor antigens can lead to tumor escape and growth even in
the presence of a robust antigen-specific anti-tumor immune
response (Kim et al., 1975; Stackpole et al., 1980). One solution is
to utilize long peptides containing multiple short TAA epitopes
(Slingluff, 2011), although such an approach has yet to be
widely adopted for self-adjuvanting glycopeptide cancer vaccines.
BenMohamed and colleagues showed reduced tumor burden
and increased survival in response to self-adjuvanting vaccines
containing four copies of the TN antigen in concert with a
CD8 epitope from the breast cancer antigen human epidermal
growth factor receptor 2 (Her2) and the pan HLA DR-binding
Epitope or “PADRE” (Renaudet et al., 2010). Protection from
murine breast cancer was associated with both generations of
TACA-specific antibodies and Her2-specific, Interferon (IFN)-γ-
secreting CD8+ T cells.
Adjuvants
Most self-adjuvanting cancer vaccines have utilized lipopeptide-
derived toll-like receptor (TLR)-2 agonists as the adjuvant. Tri-
and di-palmitoylated cysteine (Pam3Cys and Pam2Cys) agonize
TLR1/2 heterodimers and TLR2/6 heterodimers, respectively,
leading to signaling via the NF-κB pathway and APC activation.
Monopalmitoylated peptides (Bettahi et al., 2009) and lipoamino
acids (Abdel-Aal et al., 2012) have also been investigated, which
both signal via TLR2.
We recently reported the synthesis and evaluation of
self-adjuvanting vaccines containing macrophage-activating
lipopeptide 2 (MALP2), which contains Pam2Cys as part of the
structure (McDonald et al., 2014). Interestingly, we observed
very high titers of class-switched, MUC1-specific antibodies
in response to MALP2-containing vaccines in the absence
of a helper T cell epitope and the absence of a measurable
Th cell response, indicative of a T cell-independent humoral
response.
Boons and coworkers compared MUC1 conjugate vaccines
containing unmethylated CpG nucleotides, a TLR9 agonist,
to Pam3CysSKKK (Abdel-Aal et al., 2014). They found that,
although vaccines containing CpG could induce MUC1-specific
antibodies, those antibodies were less efficient at inducing ADCC
against cancer cell lines than antibodies raised against Pam3Cys-
containing vaccines. Furthermore, Pam3Cys-containing vaccines
led to a reduction of mouse mammary tumor burden and
induced CTLs capable of killing MUC1-overexpressing cell lines,
neither of which was observed after treatment with CpG-
containing vaccines. The authors hypothesized that the increased
efficacy of Pam3Cys-containing vaccines over CpG-containing
vaccines might be due to the ability of TLR2 agonists to reduce
the function of regulatory T cells.
Monophosphoryl lipid A (MPLA) is a TLR4 agonist derived
from bacterial lipopolysaccharide. Guo and coworkers reported
the synthesis and evaluation of self-adjuvanting vaccines
consisting of MPLA conjugated to the 2,3-ST (Wang et al., 2012)
and STN (Zhou et al., 2014) TACAs. The MPLA conjugates
induced TACA-specific IgG antibodies capable of recognizing
cancer cells.
A few studies have investigated the interaction between self-
adjuvanting vaccines and traditional experimental vaccines. The
adjuvant QS-21 in combination with a Pam3Cys-containing
vaccine was shown to lead to Th2 polarization compared to
the vaccine alone, but induced similar levels of MUC1-specific
IgG antibodies (Lakshminarayanan et al., 2012). Surprisingly, in
some instances the inclusion of CFA actually led to inhibition
of self-adjuvanting vaccine immunogenicity (Huang et al., 2012;
Cai et al., 2013), while in others CFA inclusion led to increased
antibody production (Abdel-Aal et al., 2012). Similarly, co-
injection of MPLA conjugates with Titermax gold completely
abrogated anti-TACA immunity (Wang et al., 2012; Zhou et al.,
2014).
Synthesis
Generally, chemical approaches for the synthesis of tumor
antigens containing TACAs have involved incorporation of
suitably protected glycosylserine/threonine residues into nascent
peptides via Fmoc-strategy solid phase peptide synthesis (SPPS),
with deprotection of the carbohydrates after cleavage of the
crude glycopeptide from resin. Various syntheses of TN, STN,
T, and ST TACA-derived amino acids for incorporation into
SPPS have been reported to date (Brocke and Kunz, 2002;
Dziadek and Kunz, 2004; Wilkinson et al., 2010; Corcilius and
Payne, 2013; Wilson and Danishefsky, 2013). It should be noted
that incorporation of TACAs has also been achieved through
chemoenzymatic means (Bézay et al., 2001; Sorensen et al., 2006;
Bello et al., 2014).
The most challenging step in the development of self-
adjuvanting vaccines is often the conjugation of (glyco)peptide
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antigens to lipopeptide adjuvants. The direct incorporation of
lipidated adjuvants such as Pam2Cys and Pam3Cys into short
peptides via SPPS works well (Metzger et al., 1991), including
through the use of microwave-assisted SPPS (Thompson et al.,
2015). However, longer self-adjuvanting vaccine constructs often
produce complex mixtures which are difficult to purify. We have
reported the efficient synthesis of such vaccines via the fragment
condensation of suitably protected (glyco)peptide fragments
activated at the C-termini as pentafluorophenyl esters (Wilkinson
et al., 2010). This approach generated the desired self-adjuvanting
vaccine candidates in good to excellent yields, but is incompatible
with unprotected lysine side-chains (which could undergo
unwanted fragment condensation reactions), necessitating the
purification of protected lipopeptide fragments using normal-
phase HPLC. Li and coworkers utilized a side-chain deprotected,
iodoacetylated Pam3Cys-Ser-(Lys)5 to conjugate unprotected
Pam3Cys to MUC1 glycopeptide 20-mers via a thioether linkage
in moderate to good yields (Cai et al., 2013).
Boons and coworkers have reported the synthesis of vaccine
constructs containing Pam3Cys via liposome-mediated native
chemical ligation (NCL) (Ingale et al., 2006). The use of
dodecylphosphocholine liposomes was necessitated by the
insolubility of Pam3Cys-containing peptides in ligation buffer.
While this approach has the benefit of chemoselectivity, it
requires formulation of each ligation fragment into liposomes,
followed by HPLC after each ligation to separate the ligation
products from the liposomal components.
Higher-order Structures
Another major factor that underlies choice of adjuvant is
the higher-order structure of the vaccine constructs. Peptide
amphiphiles have long been known to form ordered structures
in solution, and it has been demonstrated that MUC1
glycolipopeptide-based self-adjuvanting vaccines can form stable,
ordered nanoparticles in solution (Wilkinson et al., 2012). The
long lipid chains of TLR2 agonists support the formation of
such structures through hydrophobic interactions. Moreover, the
multivalent presentation of adjuvant and antigen moieties that
results from such structures is likely to be important for the
activation of APCs (Bachmann and Jennings, 2010; Oyewumi
et al., 2010) and possibly underpins the differences in vaccine
efficacy between various classes of adjuvant.
The location of the lipid-containing adjuvant within
self-adjuvanting vaccines has ramifications for the resultant
immune response. BenMohamed and coworkers found that
a linear glycolipopeptide led to increased IFN-γ production
by CD8+ T cells and inhibition of tumor growth compared
to a branched analog (Renaudet et al., 2010). The authors
demonstrated in vitro that this was associated with a difference
in uptake by DCs. Furthermore, the authors showed that
the two vaccines were subject to different cross-presentation
pathways, which may explain the difference in DC and
T cell activation observed. Similarly, Toth and coworkers
found significantly higher TN-specific antibodies in response
to a linear vaccine construct than a branched construct
(Abdel-Aal et al., 2012). In a more recent study (Eskandari
et al., 2015), the same group found that the location of the
TLR-2 agonist in the middle or at the terminus of similar
constructs containing ovalbumin model antigens controlled the
physical properties of the self-assembled particles observed in
solution.
Li and colleagues synthesized a range of vaccine constructs
containing full-length MUC1 VNTR glycopeptides conjugated
to the Q11 peptide aggregation sequence (Huang et al., 2012).
The resulting constructs formed well-defined fibrils over 200 nm
in length, irrespective of glycosylation pattern. These constructs
were able to induce MUC1-specific, class-switched antibodies in
the absence of a canonical adjuvant, and were capable of inducing
complement-dependent lysis of MCF-7 breast cancer cells, while
T cell responses to the vaccines were not reported. IgG antibody
titers induced by these constructs were 1–2 orders of magnitude
lower than those typically seen for vaccines containing a TLR2
agonist (Ingale et al., 2007;Wilkinson et al., 2011; Cai et al., 2013).
Nonetheless, it remains an excellent example of the importance
of higher-order structure andmultivalent antigen presentation to
the immune response elicited by conjugate vaccines.
It is clear from these studies that the formation of higher-
order structures by self-adjuvanting vaccines plays an important
role in their immunogenicity. To date, however, the relationships
between vaccine primary structure, higher-order organization
in solution, and resulting immunological response are poorly
understood, and should serve as an important subject for study
in the future to better understand immune stimulation by self-
adjuvanting constructs.
CONCLUSIONS AND OUTLOOK
Self-adjuvanting glycopeptide cancer vaccines are a promising
avenue for the prevention and treatment of human cancers.
Here, we have briefly highlighted selected literature examples that
showcase the design, synthesis and immunological evaluation of
such vaccines.
The antigens incorporated into self-adjuvanting cancer
vaccines range from clustered copies of the TN antigen to
truncated MUC1 B cell epitopes to full copies of glycosylated
MUC1VNTR. Although each of these antigens has been shown
to generate potent humoral immune responses, few studies
have reported induction of T cell-mediated immunity toward
MUC1-expressing cells. It will be important to dissect the
relative contribution of these two types of adaptive immune
responses in both the prophylactic and therapeutic treatment of
MUC1-expressing tumors. A major goal moving forward should
be to maximize the anti-tumor CTL response, which appears
to be particularly important in achieving this objective. The
field would benefit from a comprehensive analysis of how the
location and identity of MUC1 TACAs influences anti-tumor
immune responses in order to design vaccines which produce
optimal humoral and cell-mediated immunity. Furthermore, the
development of multi-antigenic vaccines could engage both
the humoral and cellular arms of the immune system while
diversifying the range of TAAs targeted.
Most of the studies reviewed here utilized TLR2 agonists,
including tri- di- and mono-palmitoylated cysteine, lipoamino
acids, and MALP2. All of these adjuvants in isolation have shown
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efficacy for the induction of immune responses to conjugated
TAAs, but very few studies have compared the effects of different
conjugated adjuvants. In one such study, Pam3Cys was shown to
be superior to CpG, a TLR9 agonist, in similar conjugate vaccines
containing adjuvant, a MUC1VNTR epitope and a helper T cell
epitope.
The use of lipidated amino acids in self-adjuvanting vaccines
leads to highly amphiphilic molecules, which can form higher-
order structures in solution. Such molecular organization can
give rise to multimeric antigen presentation, and contribute
to vaccine efficacy. A number of solutions have arisen to
combat the purification difficulties which can also arise from
such amphiphilic molecules, but a general method for the
simple conjugation and purification of glycolipopeptides from
purified, unprotected fragments would be invaluable for further
development of self-adjuvanting vaccines.
In conclusion, the studies reviewed here collectively
demonstrate that self-adjuvanting glycopeptide cancer vaccines
are promising targets for the prevention and treatment of cancer.
Improved synthetic routes and new methodologies for the
production of glycolipopeptides have made and will continue
to make self-adjuvanting vaccines synthetically feasible. In
concert with this, in vivo studies investigating the efficacy of
different combinations of adjuvants and antigens have led to the
production of conjugate vaccines capable of eliciting high-titer
antibodies and potent CTL responses. In the future, we envisage
these studies will inform the translation of self-adjuvanting
glycopeptide cancer vaccines into the clinic, while providing the
basis for novel experimental therapies incorporating new cancer
antigens.
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